Transaction · 0001140361-26-001239

Venker Eric

Venker Eric, PRES, IC, reported an open-market or private sale at Roivant Sciences Ltd. involving 200000.000000 shares for an estimated $4384000.00. Reported holdings after the transaction were 1654597.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SPRES, IC
ROIVRoivant Sciences Ltd.
Filing timeJan 15
Trade dateJan 12, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

ROIV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ROIV since 2026-01-15Filed 231 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001140361-26-001239
Common Shares
Transaction date
Jan 12, 2026
Filed Jan 15, 2026, 02:00 AM · 3d delay
Shares
200k sh
$2.19k per share
Estimated value
-$438M
Computed from shares × price
Holdings after
1.65M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Sale
+6score
Filing-only score

+6

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & Immunovant CEO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provi…

  2. F2

    Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencem…

Original filing · 0001140361-26-001239
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ROIV